Literature DB >> 16107838

Hepatitis C and liver transplantation.

Robert S Brown1.   

Abstract

Liver transplantation is a life-saving therapy to correct liver failure, portal hypertension and hepatocellular carcinoma arising from hepatitis C infection. But despite the successful use of living donors and improvements in immunosuppression and antiviral therapy, organ demand continues to outstrip supply and recurrent hepatitis C with accelerated progression to cirrhosis of the graft is a frequent cause of graft loss and the need for retransplantation. Appropriate selection of candidates and timing of transplantation, coupled with better pre- and post-transplant antiviral therapy, are needed to improve outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 16107838     DOI: 10.1038/nature04083

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  106 in total

1.  Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate.

Authors:  Jieyun Jiang; Wei Cun; Xianfang Wu; Qing Shi; Hengli Tang; Guangxiang Luo
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Early diagnosis and treatment resolved cholestatic hepatitis C without fibrosis after living donor liver transplantation: report of a case.

Authors:  Takasuke Fukuhara; Kazutoyo Morita; Kazuki Takeishi; Takeo Toshima; Kenji Umeda; Shigeyuki Nagata; Keishi Sugimachi; Toru Ikegami; Tomonobu Gion; Yuji Soejima; Akinobu Taketomi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

3.  [Sequelae of organ transplantation].

Authors:  S Ciesek; M Manns; C Strassburg
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

4.  Identification of novel human kinases that suppress hepatitis C virus infection.

Authors:  A Lee; S Liu; T Wang
Journal:  J Viral Hepat       Date:  2013-11-10       Impact factor: 3.728

5.  Hepatitis C and liver transplantation.

Authors:  G Tsoulfas; I Goulis; D Giakoustidis; E Akriviadis; P Agorastou; G Imvrios; V Papanikolaou
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

6.  Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.

Authors:  Daire O'Shea; John Law; Adrian Egli; Donna Douglas; Gary Lund; Sarah Forester; Joshua Lambert; Mansun Law; Dennis R Burton; D L J Tyrrell; Michael Houghton; Atul Humar; Norman Kneteman
Journal:  Liver Transpl       Date:  2016-01-29       Impact factor: 5.799

7.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

Authors:  Timothy Sheahan; Naoko Imanaka; Svetlana Marukian; Marcus Dorner; Peng Liu; Alexander Ploss; Charles M Rice
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

8.  Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience.

Authors:  Sinziana Dumitra; Salleh I Alabbad; Jeffrey S Barkun; Teodora C Dumitra; Dimitrios Coutsinos; Peter P Metrakos; Mazen Hassanain; Steven Paraskevas; Prosanto Chaudhury; Jean I Tchervenkov
Journal:  HPB (Oxford)       Date:  2013-03-14       Impact factor: 3.647

9.  Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.

Authors:  Christopher J Hoffmann; Aruna K Subramanian; Andrew M Cameron; Eric A Engels
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

Review 10.  Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.

Authors:  Jan Peveling-Oberhag; Stefan Zeuzem; Wolf Peter Hofmann
Journal:  Med Microbiol Immunol       Date:  2009-11-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.